

Piloting a Mobile Platform in Multiple Sclerosis Patients Taking Oral Disease-Modifying Therapies

INTRODUCTION

BACKGROUND

- One of the current major challenges in multiple sclerosis (MS) care is the accurate monitoring of patient symptoms and status because annual or biannual clinic visits provide only limited information.
- There is increasing interest regarding "real-time" data collection platforms, such as smartphones, as they provide the opportunity to collect more frequent, granular information.

OBJECTIVE

• To investigate the feasibility of a mobile application to collect clinical data from patients with MS and to examine the impact of mobile pop-up reminder on oral disease-modifying therapies (DMTs) adherence.

METHODS

PARTICIPANTS

A total of 60 MS patients were recruited from the Partners MS Center, Brigham and Women's Hospital. Including those:

- With a diagnosis of clinically definite MS according to the 2010 McDonald criteria
- Taking or starting either teriflunomide, fingolimod, or dimethyl fumarate
- 18-60 years of age and using a smartphone
- Enrolled in the <u>Comprehensive</u> <u>Longitudinal</u> <u>Investigation</u> of <u>Multiple</u> Sclerosis at the <u>Brigham and Women's Hospital (CLIMB) study</u>, an ongoing observational study collecting data since the year 2000

Among the 60 MS patients recruited, 10 were excluded for three main reasons (see Figure 1.)

PILL REMINDERS

Patients were 1:1 randomized in two groups: receive medication reminders on their smartphones or no reminder and followed for 6 months.


DAILY QOL

- During the 6 month period, subjects also completed items related to quality of life (QOL), mood, fatigue, cognition, and MS-specific symptoms on their mobile device.
- In particular, subjects rated their QOL daily on a 1-10 scale and every 8 days answered questions related to mood, fatigue, cognition, and MS symptom severity using their mobile device.

STATISTICAL ANALYSIS


Categorical variables were described by counts and percentages and continuous variables by mean and standard deviation (SD). To compare the pill count method (pill bags brought vs self-reported) between the those who received medication reminders on their smartphones vs those who did not, we used a chi-squared test. To compare the binary pill count (≤ 4 pills vs >4 pills) between the two groups, we used Fisher's exact test. To compare the numeric pill count (range 0-35), we used the Mann-Whitney U test. Significance levels were evaluated at an alpha level of <0.05. Statistical analyses were performed using the SAS 9.4 software (SAS Inc., Cary, NC).

Devin S. Mullin, BS¹, Cindy Gonzalez, MPH¹, Taylor J. Saraceno, BS¹, Kelsey Rankin, BA², Eyal Bartfeld, DMD, PhD,³ Brian C. Healy, PhD¹, Riley Bove, MD² and Tanuja Chitnis, MD¹, (1) Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, (2) University of California San Francisco, San Francisco, CA, (3) Irody, Inc., Boston, MA



				RESULTS-III	Table 2. Pill counts and methods,	stratified by rando	omized pill re	minder
vendie ebeveetevieti		aiaata atuatifia	al lav		Variables	Randomized	Randomized	p-value
raphic characteristi randomizat	-	ojects, stratifie	ару		Pill count method, n(%) ¹	Yes	No	
Tandonnzat		Developsized			Pill bag brought in	15(57.69%)	11(45.83%)	0.3796 ^a
	Randomized Yes	Randomized No	p-value		Patient reported Pill Count (bag & self-reported), n(%) ¹	7(26.92%)	9(37.50%)	
	26 (52.00%)	24 (48.00%)			≤4 pills	18(69.23%)	18(75.00%)	0.6653 ^b
an ± SD)	42.30±11.10	42.31±9.59	0.9985 ^a		>4 pills Pill Count (bag & self-reported), n(%) ¹	4(15.38%)	2(8.33%)	
line visit (mean ± SD)	15.64±7.95	13.46±7.22	0.3209 ^a		0	10(38.46%)	12(50.00%)	0.2940 ^c
	6(23.08%) 18(69.23%)	6(25.00%) 23(95.83%)	0.8736 ^b 0.0244 ^c		1 2	2(7.69%) 0(0.00%)	1(4.17%) 2(8.33%)	
(%)	25(96.15%)	23(95.83%)	0.9998 ^c		3	4(15.38%)	1(4.17%)	
ean ± SD)	2.19±1.18	2.00±1.64	0.5726 ^d		4 5	2(7.69%) 1(3.85%)	2(8.33%) 0(0.00%)	
line visit, n(%)	26(100.00%)	23(95.83%)	0.4800 ^c		6	0(0.00%)	1(4.17%)	
2	0(0.00%)	1(4.17%)	0.4000		10 14	0(0.00%) 1(3.85%)	1(4.17%) 0(0.00%)	
		, , ,			23	1(3.85%)	0(0.00%)	
	2(7.69%)	0(0.00%) 14(59.22%)	0.5475°		35 Legend: ^a Proportions were compared via a chi-s	1(3.85%)	0(0.00%) v tables: ^b Proportic	ons were
	16(61.54%) 8(30.77%)	14(58.33%) 10(41.67%)			compared via a Fisher's exact test for contingen	cy tables; ^c Rank scores we	ere compared via th	ne Mann-
ability status scale, DMT=c	,		e compared		Whitney U test; ¹ 42 subjects had reported pill c had unknown values and were excluded.	ount method and were ind	cluded in this analy	sis, 8 subject
roportions were compared	•	• ·						
d via a Fisher's exact test fo t.	or contingency table	es; "Rank scores wer	e compared					
				CONCLUSIO	Ν			
					trates that a mobile applicat	ion is a foasibl	a and acco	ontoblo in
					trates that a mobile applicat			splane in
				patients.				
				FUTURE DIR	FCTIONIS			
					udy directions are to investi			
				without pill remind	ders and compare smartphon	e daily QOL da	ata with Pa	rtners MS
				data.				
n of Daily QOL Pres	ent by Randor	nized Pill Remi	inder	DISCLOSURE	:5			
of Daily QOL Prese	nt hy Randomia	ed Pill Remine	ler	Mullin, Saraceno, F	Rankin: nothing to disclose.			
or Daily QOL Treser				Gonzalez receives	salary support from Verily.			
0.00				Bartfeld is employ	ed by <mark>Irody, Inc</mark> ., who provide	ed the technolo	ogy platfor	m for this
92% 92%				Healy has served a	is a consultant for Biogen Ide	c and receives	research s	upport fr
83%	79% 81%				e, and Google Life Sciences.			
					s a consultant for Sanofi-Ge	nzvme. Roche	e-Genente	ch and N
		69%			d research support from EMI			
					d Roche-Genentech. She serv			-
					and Roche-Genentech.			
		46%		Garren Gerizynne, d				
				SUPPORT				
				JUFFUNI				
			15%	We would like to than	k the Consortium of Multiple	Sclerosis Cent	ers for the	ir suppor
days 090 days	120 days	150 days 13	33 days					
Randomized pill remi	nder 🔳 no 🔲 y	/es						
								Doct
							K	Poste
								Cont
					PATHWAYS			dmu
				THE CONSORTIUM	OF		5 1813	
				MULTIPLE SCLEROSIS C	ENTERS]

DECI II TC III



intervention for MS

adherence with or MS Center clinic QOL

nis study.

from Merck Serono,

Novartis.

sulting fees from rd for Novartis,

ort with this project.



ster Number: SX04 ntact: ullin@partners.org